CAMP4 Therapeutics

Update in progress

CAMP (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Camp4 Therapeutics Corporation is a clinical‑stage biopharmaceutical company that discovers and develops RNA‑based therapies for genetic diseases. Its lead candidate, CMP‑001, is in a Phase 1/2 trial for urea cycle disorders, and the company is also developing CMP‑002 for SYNGAP1‑related disorders. Formerly Marauder Therapeutics, it renamed to Camp4 Therapeutics in March 2018. It was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive